UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

The lancet oncology, 2010-08, Vol.11 (8), p.733-740

2010

Volltextzugriff (PDF)

Clinicopathologic Features of Advanced Squamous NSCLC

Journal of thoracic oncology, 2016-09, Vol.11 (9), p.1411-1422

2016

Volltextzugriff (PDF)

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2006-11, Vol.24 (31), p.5034-5042

2006

Volltextzugriff (PDF)

Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

Lung cancer (Amsterdam, Netherlands), 2011-07, Vol.73 (1), p.11-17

2011

Volltextzugriff (PDF)

ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

European journal of cancer (1990), 2012-05, Vol.48 (7), p.961-973

2012

Volltextzugriff (PDF)

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4787-4792

2009

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.373-384

2013

Volltextzugriff (PDF)

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Clinical cancer research, 2006-10, Vol.12 (20), p.6049-6055

2006

Volltextzugriff (PDF)

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.211-218

2014

Volltextzugriff (PDF)

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

Journal of thoracic oncology, 2018-02, Vol.13 (2), p.228-236

2018

Volltextzugriff (PDF)

Lung cancer after treatment for breast cancer

The lancet oncology, 2010-12, Vol.11 (12), p.1184-1192

2010

Volltextzugriff (PDF)

Lung cancer after treatment for Hodgkin's lymphoma: a systematic review

The lancet oncology, 2005-10, Vol.6 (10), p.773-779

2005

Volltextzugriff (PDF)

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Clinical lung cancer, 2018-07, Vol.19 (4), p.331-339

2018

Volltextzugriff (PDF)

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2008-04, Vol.3 (4), p.430-440

2008

Volltextzugriff (PDF)

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2009-04, Vol.64 (1), p.60-65

2009

Volltextzugriff (PDF)

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7500-7500

2013

Volltextzugriff (PDF)

Where next for gefitinib in patients with lung cancer?

The lancet oncology, 2006-06, Vol.7 (6), p.499-507

2006

Volltextzugriff (PDF)

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Journal of thoracic oncology, 2018-02, Vol.13 (2), p.165-183

2018

Volltextzugriff (PDF)

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

The Lancet (British edition), 2005-10, Vol.366 (9496), p.1527-1537

2005

Volltextzugriff (PDF)

Targeting blood vessels for the treatment of non-small cell lung cancer

Current cancer drug targets, 2008-08, Vol.8 (5), p.392-403

2008

Volltextzugriff (PDF)

Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20708-e20708

2019

Volltextzugriff (PDF)

Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non–Small Cell Lung Cancer

Clinical cancer research, 2005-07, Vol.11 (13), p.5051s-5056s

2005

Volltextzugriff (PDF)

1 – 25 von 149

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Englisch
(147)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(87)
Humans
(83)
Oncology
(73)
Lung Neoplasms - Drug Therapy
(54)
Female
(43)
Male
(43)
Middle Aged
(40)
Aged
(38)
Biological And Medical Sciences
(37)
Medical Sciences
(36)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(33)
Adult
(32)
Lung Neoplasms - Pathology
(32)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(30)
Respiratory System
(23)
Pneumology
(21)
Carcinoma, Non-Small-Cell Lung - Pathology
(20)
Chemotherapy
(20)
Lung Neoplasms - Mortality
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Clinicopathologic Features of Advanced Squamous NSCLC

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

Lung cancer after treatment for breast cancer

Lung cancer after treatment for Hodgkin's lymphoma: a systematic review

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer

Where next for gefitinib in patients with lung cancer?

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Targeting blood vessels for the treatment of non-small cell lung cancer

Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study

Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non–Small Cell Lung Cancer

Suchergebnisse filtern